RxDoctor Payments Data

Jennifer Graslie, PA

Physician Assistant · Sheridan, WYNPI 1699959593

Payments from drug & device makers

What this record shows

Medtronic accounts for 87.4% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $1,776 and has fallen 86.9% since, to $232 in 2025. Among physician assistant clinicians in WY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,599in general payments, 2019–2025

Across 41 payments — averaging $87.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Edwards Lifesciences$211
  • Impulse Dynamics (USA) Inc.$66
  • Novartis$54
  • Boston Scientific$49
  • Actelion Pharmaceuticals US, Inc.$39
  • plus $33 from 2 others

What the payments were for

  • Travel & lodging$2,12959%
  • Food & beverage$1,47041%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,599 in reported general payments places this provider in the 95th percentile of 203 physician assistant providers in Wyoming.

See all physician assistant providers in Wyoming

Medicare billing

Part B allowed, 2024
$110,589
Medicare patients
486
Services billed
1,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban216$177,761
EntrestoSacubitril/Valsartan63$47,970
XareltoRivaroxaban66$46,342
Repatha SureclickEvolocumab25$14,249
FarxigaDapagliflozin Propanediol17$12,985
Praluent PenAlirocumab24$11,225
BrilintaTicagrelor15$7,634
Potassium Chloride209$6,209
Ezetimibe94$3,334
Metoprolol Succinate209$2,658
Atorvastatin Calcium171$1,748
Losartan Potassium166$1,506
Carvedilol169$1,161
Ranolazine ErRanolazine15$1,089
ClopidogrelClopidogrel Bisulfate104$910

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$54$47,97063 claims
AstraZenecaFarxiga, Brilinta$12$20,61832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 203 physician assistant providers in Wyoming.

Other physician assistant in Sheridan

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →